NovoCure Ltd 2026年季度报告

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has beensubject to such filing requirements for the past 90 days. Yes☒No☐. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and“emerginggrowthcompany”inRule12b-2oftheExchangeAct. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS In addition to historical facts or statements of current condition, this report contains forward-looking statements within the meaningof Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.Forward-looking statements contained in this report are based on our current plans, expectations, hopes, beliefs, intentions orstrategies concerning future developments and their impact on us. Forward-looking statements contained in this report constituteour expectations or forecasts of future events as of the date this report was filed with the Securities and Exchange Commissionand are not statements of historical fact. You can identify these statements by the fact that they do not relate strictly to historical orcurrent facts. Such statements may include words such as "anticipate," "will," "estimate," "expect," "project," "intend," "should," •our research and development, clinical study and commercialization activities and projected expenditures; •the further commercialization of our Products for current and future indications; •our business strategies and the expansion of our sales and marketing efforts in the United States ("U.S.") and in other •the market acceptance of our Products for current and future indications by patients, physicians, third-party payers andothers in the healthcare and scientific community; •our plans to pursue the use of our Products for the treatment of indications other than glioblastoma ("GBM"), pancreaticcancer, non-small cell lung cancer ("NSCLC"), brain metastases from NSCLC, and malignant pleural mesothelioma •our estimates regarding revenues, expenses, capital requirements and needs for additional financing; •our ability to obtain regulatory approvals for the use of our Products in indications other than GBM, NSCLC, MPM andpancreatic cancer; •our ability to acquire from third-party suppliers the supplies needed to manufacture our Products;•our ability to manufacture adequate supply of our Products; •our ability to secure and maintain adequate coverage from third-party payers to reimburse us for our Products for currentand future indications; •our ability to receive payment from third-party payers for use of our Products for current and future indications;•our ability to maintain, develop, protect, defend or enforce our intellectual property position; •our ability to manage the risks associated with business disruptions caused by natural disasters, extreme weather events,pandemics such as COVID-19 (coronavirus), international conflict, a prolonged failure of U.S. lawmakers to agree on abudget or appropriation legislation to fund the federal government’s operations (also known as a government shutdown), •our prospects, financial condition and results of operations. These forward-looking statements involve a number of risks and uncertainties (some of which are beyond our control) or otherassumptions that may cause actual results or performance to be materially different from those expressed or implied by theseforward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptionsprove incorrect, actual results may vary in material respects from those projected in these forward-looking statements.Factorswhich may cause such differences to occur include those risks and uncertainties set forth under Part I, Item 1A., “Risk Factors” in TRADEMARKS This Quarterly Report on Form 10-Q includes trademarks of NovoCure Limited and other persons. All trademarks or trade namesreferred to herein are the property of their respective owners. Quarterly Report on Form 10-QTABLE OF CONTENTS PART I—FINANCIAL INFORMATION PART II—OTHER INFORMATION PART I—FINANCIAL INFORMATION Table of Contents Table of Contents NOVOCURE LIMITED AND SUBSIDIARIESNOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSU.S. dollars in